Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan
暂无分享,去创建一个
D. Aquino | L. Cuppini | G. Finocchiaro | M. Eoli | M. Bruzzone | Alessandro M Scotti | E. Anghileri | A. D. Di Stefano
[1] B. Rosen,et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation , 2013, Proceedings of the National Academy of Sciences.
[2] E. Prodi,et al. Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan , 2013, PloS one.
[3] M. Gilbert,et al. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. , 2013, Neuro-oncology.
[4] L. Ellis,et al. Predictive Biomarkers for Bevacizumab: Are We There Yet? , 2013, Clinical Cancer Research.
[5] D. Yousem,et al. ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?--a meta-analysis. , 2013, AJR. American journal of roentgenology.
[6] G. Bergers,et al. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. , 2013, CNS oncology.
[7] A. Matsumura,et al. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab. , 2013, Acta neurochirurgica. Supplement.
[8] Albert Lai,et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.
[9] W. Mason,et al. Antiangiogenic therapies in glioblastoma multiforme , 2012, Expert review of anticancer therapy.
[10] Tracy T Batchelor,et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. , 2012, Cancer research.
[11] Soonmee Cha,et al. Imaging diagnosis of brain metastasis. , 2012, Progress in neurological surgery.
[12] P. Specenier. Bevacizumab in glioblastoma multiforme , 2012, Expert review of anticancer therapy.
[13] J. Debbins,et al. Correlations between Perfusion MR Imaging Cerebral Blood Volume, Microvessel Quantification, and Clinical Outcome Using Stereotactic Analysis in Recurrent High-Grade Glioma , 2012, American Journal of Neuroradiology.
[14] P. Carmeliet,et al. Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.
[15] M S Brown,et al. Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma , 2011, American Journal of Neuroradiology.
[16] Timothy D Johnson,et al. Prospective Analysis of Parametric Response Map–Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment , 2011, Clinical Cancer Research.
[17] Edward S. Kim,et al. Bevacizumab: current updates in treatment , 2010, Current opinion in oncology.
[18] S. Maier,et al. Diffusion imaging of brain tumors , 2010, NMR in biomedicine.
[19] Timothy D Johnson,et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Raizer,et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. , 2010, Radiology.
[22] A. Jackson,et al. Enhancing Fraction in Glioma and Its Relationship to the Tumoral Vascular Microenvironment: A Dynamic Contrast-Enhanced MR Imaging Study , 2010, American Journal of Neuroradiology.
[23] M. Chamberlain. Radiographic patterns of relapse in glioblastoma , 2010, Journal of Neuro-Oncology.
[24] Timothy D Johnson,et al. The parametric response map is an imaging biomarker for early cancer treatment outcome , 2009, Nature Medicine.
[25] Douglas C. Miller,et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.
[26] Glyn Johnson,et al. Comparison of region‐of‐interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas , 2007, Journal of magnetic resonance imaging : JMRI.
[27] G Johnson,et al. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. , 2007, AJNR. American journal of neuroradiology.
[28] Bradford A Moffat,et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[29] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[30] M. Ichihara,et al. Expression of CD109 in human cancer , 2004, Oncogene.
[31] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[32] G Johnson,et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. , 2000, AJNR. American journal of neuroradiology.
[33] M Takahashi,et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. , 2000, AJNR. American journal of neuroradiology.